reference/30193487

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/30193487

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Journal Article
endingPage	1538
issn	0923-7534
issueIdentifier	9
pageRange	1529-1538
publicationName	Annals of oncology : official journal of the European Society for Medical Oncology
startingPage	1529
bibliographicCitation	Candelaria M, Gallardo-Rincón D, Arce C, Cetina L, Aguilar-Ponce JL, Arrieta O, González-Fierro A, Chávez-Blanco A, de la Cruz-Hernández E, Camargo MF, Trejo-Becerril C, Pérez-Cárdenas E, Pérez-Plasencia C, Taja-Chayeb L, Wegman-Ostrosky T, Revilla-Vazquez A, Dueñas-González A. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol. 2007 Sep;18(9):1529–38. doi: 10.1093/annonc/mdm204. PMID: 17761710.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a0b01bf3b13e07f5d484f525873edbcf http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5c57ee8a461e5ba8696f6c0d2897d762 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0396c84e37d9de786a9589f1939bad1c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2303d40e445a481f3114c5f4610b020c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fb6cc99039716d19a1516c527525f0b7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7de6cb7bfa88de96fb2c025775cb84de http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fd1c300501e71649f8946bf656962f28 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_05ffd2ca8d38de2a1a1ffd90b118cf24 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_dc25114f154c4cb214f076f2b3366875 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_789b21c2e146b31e287b6dfc3aa32f40 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_464943d6e5ffc0ab46bb81f58efd946e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_05b0a2425f09a8a44f90ff6deead7145 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4d535b462a57c5260e87fb82da963a33 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cee8cadfe4916e901a22457038b21e97 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2ffe5f8e852959cebb0541d61ea2968a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ee8d5744ad5dc53a9a2c8f6a1e9e36b5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8c62bcc3e373760d25bd909ab770b729
date	200709
identifier	https://doi.org/10.1093/annonc/mdm204 https://pubmed.ncbi.nlm.nih.gov/17761710
isPartOf	https://portal.issn.org/resource/ISSN/0923-7534 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/1846
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors
discusses	http://id.nlm.nih.gov/mesh/M0010420 http://id.nlm.nih.gov/mesh/M0010676 http://id.nlm.nih.gov/mesh/M0022501
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D019008 http://id.nlm.nih.gov/mesh/D014635Q000008 http://id.nlm.nih.gov/mesh/D000971Q000627 http://id.nlm.nih.gov/mesh/D009369Q000188 http://id.nlm.nih.gov/mesh/D006830Q000008
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D006655Q000378 http://id.nlm.nih.gov/mesh/D014635Q000009 http://id.nlm.nih.gov/mesh/D006830Q000009 http://id.nlm.nih.gov/mesh/D014635Q000097 http://id.nlm.nih.gov/mesh/D044127 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D006830Q000097 http://id.nlm.nih.gov/mesh/D019175 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D009369Q000235 http://id.nlm.nih.gov/mesh/D000293 http://id.nlm.nih.gov/mesh/D006801
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2187 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID36314 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2907 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID13200033 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID31703 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5311497 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5702198 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60750 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3637 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60700 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60780 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID46931011 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3121 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID71296871 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID147515 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID426756 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7156 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID44424639 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16760703 http://rdf.ncbi.nlm.nih.gov/pubchem/protein/EC_3.5.1.98 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID73265388 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3549980 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135410875 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5672

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129221764 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135945851 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129769972 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128706830 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID136123131 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129347572

Total number of triples: 86.